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Heterologous anti-lymphocytic antiserum  is  a  potent  immunosuppressive 
agent capable of prolonging the survival of allografts in experimental animals 
(1, 2, 4, 5, 7) and man (3). The mechanism of action of the antiserum, however, 
remains obscure. In particular, experimental evidence has varied concerning the 
significance of lymphopenia during the period of immunosuppression (4-8). 
One approach to studying the mode of action of anti-lymphocytic serum is to 
determine its effect on the cells responsible for allograft rejection. Because recent 
reports have emphasized the central role of circulating small lymphocytes in 
initiating the cellularly mediated allograft type response (9), the present experi- 
ments were undertaken to determine the effect of a rabbit anti-rat lymphocyte 
serum  on these cells.  The results indicate that the immunosuppressive effect 
of the antiserum is due (a) to a marked decrease in the number of small lym- 
phocytes available to carry out the immune response and (b) to a depression of 
the immunological competence of the remaining small lymphocyte  population. 
Several recent reports have indicated that splenic and lymph node ceils from 
mice treated with anti-lymphocytic antiserum have reduced immune potential 
(10--12). These organs normally contain a  heterogeneous population of cells; 
treatment with the antiserum usually causes a reduction in the number of small 
lymphocytes and has been reported to cause an increase in other cell types (11). 
It is difficult, therefore, to interpret to what extent the decreased immunological 
competence of the combined cell population results from the relative reduction 
of small lymphocytes and to what degree it is due to a qualitative deficiency in 
the small lymphocytes that remain. A distinction has been made in the present 
studies between these two possible effects by using thoracic duct lymphocytes 
which morphologically, at least, are relatively homogeneous. 
Materials and Methods 
Animals.--Lewis strain rats and (Lewis  ×  BN) Fx hybrids obtained from Microbiological 
Associates,  WalkersviUe,  Md., were  used  exclusively.  The antiserum was produced  in male  New 
Zealand rabbits obtained  from the NIH animal  production  unit. 
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Antisarum.--Rabbit  anti-rat  thymocyte serum  (RARTS)  was  prepared by the method 
described by Levey and Medawar  (5). Each of a  group of eight rabbits was injected intra- 
venously with 1 billion thymocytes from weanling Lewis rats, and 14 days later each rabbit 
received a  second similar intravenous injection. The rabbits were exsanguinated 7 days after 
their second injection, their sera pooled and then decomplemented by heating at 56°C for 30 
rain. The serum was absorbed for 1 hr at room temperature against Lewis red blood ceils, 
which had been washed twice in Ringer's solution, and was then filtered through a  Millipore 
filter and kept frozen at --20°C until used. 
Normal rabbit serum (NRS) was obtained from unlmmunized rabbits and handled in the 
same fashion. The dose of RARTS or NRS employed was 1.5 ml/100 g body weight and was 
given as three subcutaneous injections over a 1 rain period into the shaved back of each ether- 
anesthetized rat. It caused no detectable systemic toxicity or anemia. 
The potency of the antiserum was qualitatively demonstrated by its ability to prolong the 
survival of (Lewis X  BN) F1 grafts on Lewis hosts as follows: Six Lewis rats were grafted with 
(Lewis ×  BN)F1 skin. Two of them were given 1.5 ml/100 g body weight RARTS on days -4-2 
and A-S; two received NRS in the same dose schedule; and two were left untreated. The NRS- 
treated and untreated rats began rejecting their skin grafts between the 7th and 9th day, and 
rejection was complete in all  cases by day -4-12. The  RARTS-treated  rats had  normal ap- 
pearing grafts until days +20 and +24 when graft rejection was first noted. Graft rejections 
once underway proceeded in a normal fashion. 
Thorac~ Duot Lymplwcytes.--Lymphocytes  were  obtained  by  cannulating  the  thoracic 
ducts of male Lewis rats, weighing 200-250 g, according to the method of Wilson (13). In each 
instance, free flow of thoracic duct lymph was obtained with no evidence of clot formation or 
active bleeding. The lymph was collected in 20-100 ml of heparinized Ringer's solution main- 
tained at 4°C. The collection period for each sample, unless otherwise noted, was approximately 
24 hr. The cells were concentrated by eentrifugation and washed once in Ringer's solution. An 
aliquot of the washed cells was resuspended in 0.0S per cent trypan blue and allowed to stand 
for 3-5 rain prior to counting; those cells not stained with trypan blue were considered viable. 
Giemsa smears were also prepared from most 24 hr collections for differential counts. 
Graft vs. Host Assay.--The unpooled  thoracic duct lymphocytes,  collected within 48 hr 
after cannulation of the various donors, were injected in doses ranging from 5 to 40 million 
ceils into the orbital branch of the anterior facial vein of (Lewis X  BN)FI rats less than 24 hr 
of age. The injections were usually well tolerated. Litters  always included two noninjected 
controls. Beginning at 10 days of age, the FI hybrid animals were weighed  thrice weekly and 
inspected for signs of skin changes pathognomonlc of graft vs. host  (GVH)  reactions  (14). 
The date of death of each animal undergoing a GVH reaction was noted. Death was ascribed 
to a GVH reaction only if the animal showed characteristic thickening of the skin, followed by 
a marked dermatitis and failure to gain weight at a normal rate. Animals with these signs, sur- 
viving more than 40 days, were classified as having nonfatal GVH disease. Preliminary experi- 
ments revealed that injected rats showing no signs of GVH reactions at 40 days always con- 
tinued  to grow  normally. Because these differences in response were  clear  cut,  no further 
gradation of GVH reactions was necessary. 
Fluorescent Antibody Studies.--Preliminary  in  vitro studies were done  to  determine the 
approximate sensitivity of indirect staining with fluorescent antibody. 5 million washed tho- 
racic duct lymphocytes were resuspended in 0.2 ml Ringer's solution and incubated for 30 rain 
at 37°C with 0.1 ml of RARTS ranging in concentrations from 1:10 to 1:2560. The cells were 
then washed twice and incubated at room temperature for 20 rain with 0.1 ml of a 1:5 dilution 
of fluorescein-conjugated goat-anti-rabbit gamma globulin (kindly supplied by Dr. R. Asof- 
sky). Mter two more washings, aliquots of the cells were examined by fluorescent microscopy 
(X 950). Fluorescence was seen as a ring around the cell wall with no detectable intracellular 
localization. There was uniform staining of all cells incubated with a sufficient concentration of HEWES  D.  AGNEW  113 
PARTS, and the staining decreased as the serum was diluted. In two separate experiments, 
the highest dilutions of antiserum that gave definitely positive recations were 320 and 640 
respectively. Lymphocytes incubated with normal rabbit serum did not stain. The method was 
there/ore adopted to detect the presence of antibody on the surfaces of thoracic duct lympho- 
cytes from RARTS-treated donors (see Results). 
Pedpheral Lymphocyte Counts.--Anlmals that underwent thoracic duct cannulation were 
bled preoperatively from their tail veins, and white blood counts and differential counts were 
pedormed. Additional adult male Lewis rats not undergoing cannulation were treated with 
either RARTS or NRS in the usual dose, and their white blood counts and differential counts 
were followed serially over the enusing 3 wk. 
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FzG. 1.  Effects of a single dose of RARTS or NRS on subsequent small lymphocyte counts 
made on blood and thoradc duct lymph. Peripheral blood counts (•  and o) and thoracic duct 
lymph counts (U and [3) were done on untreated (•  and m) and RARTS-treated (O and u) 
rats.  Curves indicate average blood  (,  ~)  and  lymph counts  (  )  in RARTS- 
treated ~n~mals. 
H~stolog~al Studies.--Lymph nodes and spleens from rats sacrificed 24-48 hr after thoracic 
duct cannulation were sectioned and stained with hematoxylin and eosin. 
RESULTS 
Effect of RARTS and NRS on Peripkeral  Blood Lymphocytes and  Thoracic 
Duct Lymphocytes.--Mter a single injection of RARTS, the numbers of small 
lymphocytes in  the  peripheral  blood were  depressed  to  approximately  one 
fourth their normal level for about 10 days; thereafter they rapidly returned to 
normal (Fig.  1). Rats receiving  a single close of RARTS, whose thoracic ducts 
were cannulated 1-10 days later, showed an equally profound decrease in output 
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TABLE  I 
Average  Ratio  of Large  Lymphocytes  to Small Lyraphocytes  in  tke Blood  and  Tkoraclc  Duct 
Lymph of Untreated Rats and Rats Receiving NRS or RARTS 
Treatment 
RARTS 
RARTS 
NRS 
Un~eat~ 
N'o. days 
posttreatment 
1-10 
14-21 
3-6 
No.  rats tested 
12 
5 
4 
7 
Large lymphocyte/small  lymphocyte 
Blood  Thoracic duct 
%  % 
,~/s7  12/ss 
39/51  9/91 
42/58  ~./98 
18/82  2/98 
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FIG. 2.  Thoracic  duct  small lymphocyte output  of untreated  rats  (  ),  and  rats 
injected 6  hr after carmulation with NRS  (-- ....  )  or RARTS  (  ,  .  ). The cells were 
collected at 4, 12 and 24 In" after treatment, and the average number of cells draining per hour 
for each collection was calculated and recorded as a percentage of the pretreatment output. 
normal numbers of cells (Fig. 1). Neither blood nor thoracic duct small lympho- 
cyte counts  1 were significantly affected by a single dose of NRS. 
The treatment with KARTS also caused an appreciable increase in the ratio of 
large to small lymphocytes in both blood and thoracic duct lymph (Table I). 
1 Made 3-6 days after treatment (4 rats). m~w-~s D. ACNEW  I15 
NRS had a similar effect on blood lymphocytes without affecting the ratio in the 
thoracic duct lymph. 
Kinetics of R.ARTS-Induced  Suppression of Thoradc Duct Lymphocytes.-- 
Mter cannulation of the thoracic duct, the number of lymphocytes draining per 
hour remained relatively constant in untreated and NRS-treated rats (Fig.  2). 
In rats receiving RARTS, however, there was a significant decrease in output 
beginning approximately 4 hr after treatment. 
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FIG. 3. Average percentage of thoracic duct small lymphocytes stained with fluorescein- 
conjugated goat anti-rabbit gamma globulin  when two rats received  PARTS (  ) and 
one received  NRS (  ...... -) 6 hr after cannulation. 
During the period of maximum decline, i.e. between the 4th and 12th hr, the 
percentage of cells staining with trypan blue increased from a normal level of 
<3% to a high of approximately 18%. By 24 hr, the percentage of stained cells 
had returned to normal and remained so in all rats cannulated 1-21 days after 
treatment  (see  previous section).  No  such  increase  in  "nonviable"  (trypan 
blue-stained) cells occurred in the untreated or NRS treated controls. 
Immunofluorescent Studies.--In  rats  receiving  a  single  dose  of  RARTS, 
lymphocytes that stained with  fluorescent antibody began  to appear in the 
thoracic duct lymph 4 hr after treatment (Fig. 3). Their percentage reached a 
peak (> 95) at 10-12 hr and returned to the baseline (0) at 24 hr. No staining of 
lymphocytes occurred after the first 24 hr or after treatment with NRS. 116  ANTI-LYMPHOCYTIC  SERUM  AND  SMALL  LYMPHOCYTES 
Studies of Graft vs. Host (GVtt) Reactions.--lO million thoracic duct lympho- 
cytes  obtained  from  untreated  and  NRS-treated  Lewis  donors  consistently 
caused lethal GVH reactions in newborn (Lewis X  BN)  Fx rats,  and smaller 
doses produced graded responses (Table II). In contrast, lymphocytes collected 
TABLE II 
Incidence of GVtt Disease in (Lewis X  BN) Ft Rats Receitqng Intravenous Injections at Birth 
of  Tkoraci~ Duct  Lymphocytes  Obtained from  Normal  Donor Lewis  Rats  and  Donors 
Treated with R_ARTS  and NRS at  Various Intervals prior to Cannulation 
Treatment 
RARTS 
RARTS 
RARTS 
RARTS 
NRS 
Untreated 
No. days  No~ 
post-  '  individual 
treatment  donors 
thoracic duct  (cells not 
cannulation  pooled) 
1  3 
3-4  5 
7-10  4 
14-21  5 
3-6  4 
7 
Incidence GVH/No. F1 Injections 
Dose (X I06) 
2.5  5  10  20  40 
o/5  o/11  0/7 
0/5  O/lO  0/7 
0/8  o/lo  o/5 
21/23  23/23 10"/10 
21"/21  12"/121  4*/4 
5/13  17/19  28*/28 
* All  reactions lethal. 
TABLE III 
Incidence of Lethal and Nonlethal GVH Disease Produced in (Lewis X  BN)F1 Rats by Injection 
of Lymphocytes Obtained  from Donor Lewis Ra~ Treated 14 to 21 Days prior to Cannulation 
with a Single Injection of RARTS 
Animal 
ZZZ 
a 
b 
£ 
d 
No. days  ~uost- 
treatment thoracic 
duct cannulation 
14 
16 
17 
21 
21 
Incidence lethal GVH/Nonlethal GVH/Normal 
Dose (X  108) 
40 
31010 
1/010 
2/0/0 
21010 
2/0/0 
10  20 
4/0tl  6•0•0 
2/2/0  3/2/0 
1/1/1  3/1/0 
6/0/0  6/0/0 
3/2/0  2/0/0 
16/5/2  20/3/0  Total ..........  14-21  10/0/0 
from rats cannulated 1-10 days after RARTS treatment caused no detectable 
GVH reactions when injected in even larger doses, e.g., 40 million cells.  Lym- 
phocytes obtained from animals  14-21  days after RARTS treatment, on the 
other hand, possessed an almost normal capacity to initiate GVH reactions, al- 
though evidence of a slight immune incompetence remained (Table III). HEV~S D.  AGNEW  117 
Tke Effect of Incubating Normal L ympkocytes in Cell Free Thoracic Dnct L ympk 
from RARTS Treated Rats.--Since the lymphocytes from the KARTS-treated 
donors had been allowed to stand in a chilled mixture of lymph and  Ringer's 
solution for 24 hr prior to injection, the possibility arose that the cells had been 
rendered immunologically incompetent by the in vitro exposure to the lymph- 
Ringer's mixture, rather than by the in vivo effect of the KARTS. That this was 
not the case, however, was shown by the experiment summarized in Table IV in 
which normal ceils were exposed to similar lymph-Ringer's mixtures and were 
found to be immunologically competent. 
Histology.--Histolo~cal  sections of lymph nodes and spleens  from the rats 
TABLE IV 
Comparison of Incidence of GVH  Produced by  Thoracic Duct  Lymphocyte Population of 
RARTS-Tteated  Lewis  Donor Rat  and  Normal Thoracic Duct  Lympkocytes Allowed 
to Stand in Cell-Free Lympkatic Fluid of Same Donor 
Donor 
rat 
h 
Treatment 
RARTS 4 days prior tc 
cannulation 
RARTS 7 days prior tc 
cannuiation 
Cells injected 
Donor lymphocytes 
Normal  lymphocytes  in  lym ] 
phatic fluid of donor i* 
Donor lymphocytes 
Normal lymphocytes incu- 
bated in fluid of donor h* 
Incidence GVH/No. FI 
injection 
Dose (X 106) 
10  20  40 
0/2  0/4 
10/10 
0/6  0/1 
10/10 
* Same  number  of  normal  lymphocytes  as  donor  lymphocytes,  incubated  at  4°C  for 
24 hr. 
which received KARTS and subsequently underwent thoracic duct cannulation 
(Table I) showed a pronounced depletion of small lymphocytes. Comparison 
with sections from the control groups  (normal  and NRS)  revealed that  the 
treatment with KARTS caused a  generalized  depletion of small lymphocytes 
over and above that caused by prolonged drainage of lymph from the thoracic 
duct. 
DISCUSSION 
The results of these experiments indicate that the temporary immune suppres- 
sion occurring in rats treated with a single dose of KARTS is due to two effects 
on the small lymphocyte population: (a)  a generalized depletion of small lym- 
phocytes in the thoracic duct lymph, the blood, the spleen, and the peripheral 118  ANTI-LYMPHOCYTIC  SERUM  AND  SMALL LYMPHOCYTES 
lymph nodes,  and  (b)  a  loss of immune  competence by the remaining small 
lymphocytes. During the first 24 hr of the depletion period, rabbit antibody can 
be demonstrated on a high percentage of the small lymphocytes, many of which 
also stain with trypan blue. From the 2nd to the 10th day, it is no longer possible 
to detect the changes in staining properties, but  the numbers and immtmo- 
competence of the cells remain significantly depressed.  By the 14th day, the 
counts and behavior of the cells have returned to normal. 
The initial  rapid  reduction in  circulating small  lymphocytes that  follows 
treatment with anti-lymphocytic serum has been frequently described (4-6, 15) 
although exceptions have been reported (7). It appears to be due, at least in 
part, to immune lysis, which occurs in vitro and requires complement (15). The 
manner in which the antiserum brings about the later phases of the response has 
not been defined and requires further study. 
SUMMARY 
Treatment of Lewis strain rats with a  single  subcutaneous  dose of rabbit 
anti-rat thymocyte serum (RARTS) resulted in a marked depletion of small 
lymphocytes in the blood and thoracic duct lymph for approximately 10 days. 
While the thoracic duct lymphocytes were declining in numbers, rabbit anti- 
body could be detected on the surfaces of a high percentage of the lymph cells. 
Furthermore, the thoracic duct lymphocytes were unable to initiate graft vs. 
host reactions during the period of depletion, even when injected in extremely 
large  doses.  Approximately 2  wk after treatment,  the numbers  and immune 
competence of the small lymphocytes returned to normal. 
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